Key result
Laboratory APTT had the highest diagnostic accuracy for monitoring heparin status, but CoaguChek Plus APTT was adopted for point-of-care due to faster turnaround times.
Why the study?
What is the diagnostic accuracy of bedside coagulation procedures compared to laboratory APTT for monitoring anticoagulation status in patients receiving heparin during percutaneous coronary angioplasty?
Observational
What is the diagnostic accuracy of bedside coagulation procedures compared to laboratory APTT for monitoring anticoagulation status in patients receiving heparin during percutaneous coronary angioplasty?
While laboratory APTT has the highest diagnostic accuracy for monitoring heparin during PCI, point-of-care whole blood APTT offers a practical alternative due to inadequate laboratory turnaround times.
Answers are grounded in this paper and cite their sources.
Supports POC APTT adoption for faster heparin monitoring in PCI; leaves open prospective outcome validation before practice change.
We evaluated the diagnostic accuracy of three bedside coagulation procedures, the Hemochron activated whole-blood clotting time (ACT) (International Technidyne, Edison, NJ), the CoaguChek Plus (Boehringer Mannheim, Indianapolis, Ind) activated partial thromboplastin time (APTT) and the TAS (Cardiovascular Diagnostics, Raleigh, NC) APTT, before removal of arterial sheaths, in patients who received heparin therapy during percutaneous coronary angioplasty. As part of the postprocedure care, nurses performed bedside coagulation tests, removed the sheaths when appropriate coagulation criteria were met, and collected samples for laboratory APTT determinations and heparin assays performed with an automated chromogenic anti-Xa assay. Patients with heparin concentrations of 0.3 U/mL or more were classified as anticoagulated and those with concentrations less than 0.3 U/mL, as not anticoagulated. Analysis of the receiver operator characteristic (ROC) curve was used to rank the performance of the methods. Areas under the ROC curves +/- SE for the laboratory APTT, CoaguChek Plus APTT, Hemochron ACT, and TAS APTT were 0.978 +/- 0.016, 0.872 +/- 0.044, 0.797 +/- 0.039, and 0.795 +/- 0.048, respectively. At cutoff values for the tests that provide greatest safety for the patients (no false-negative results), the false-positive rates for the laboratory, CoaguChek Plus, Hemochron, and TAS methods were 15%, 27%, 62%, and 100%, respectively. The laboratory APTT demonstrated the highest diagnostic accuracy in this application; however, turnaround time for the test (50% of the results were reported in excess of 77 minutes) was inadequate for clinical decision making. To meet this requirement, we developed a point-of-care program using the whole blood APTT performed on the CoaguChek Plus analyzer.
No takes yet. Share an insight, caveat, or question.
Solomon et al. (1998) conducted an observational in Heparin therapy during percutaneous coronary angioplasty. Bedside coagulation procedures (CoaguChek Plus APTT, Hemochron ACT, TAS APTT) vs. Laboratory APTT was evaluated on Diagnostic accuracy (Area under the ROC curve) for detecting heparin concentrations ≥ 0.3 U/mL. Laboratory APTT had the highest diagnostic accuracy for monitoring heparin status, but CoaguChek Plus APTT was adopted for point-of-care due to faster turnaround times.
Synapse has enriched 10 related papers. Consider them for comparative context: